This would mean comparing their impacts on SLE-specific immunological biomarkers such as autoantibodies titers, complement proteins (C3, C4), cytokines such as IL-6, IL-10, and TNF-α, and T cell subsets (especially the Th17/Treg ratio), to assess efficacy and monitor disease progression, and clinical manifestations. This evidence concerns the gene IL10 and systemic lupus erythematosus.